Scientific Advisory Board

Dr. Conlon completed his undergraduate degree in genetics at Texas A&M University and his PhD in genetics/biomedical studies at the University of Florida. As the Director of the Powell Gene Therapy Center (PGTC) Toxicology Core and a member of the Pediatrics faculty for 13 years, he facilitated efficient, cost-effective, and rigorous preclinical testing of gene therapy vectors, with a special emphasis on recombinant adeno-associated virus (rAAV) vectors. Dr. Conlon has brought 14 gene therapy trials to the FDA with approval. He has been at the forefront of collaborations between the PGTC, the University of Florida College of Medicine’s Department of Pediatrics, and the University of Florida College of Veterinary Medicine to identify means for treating congestive heart failure, types of Retinal Degeneration and Glycogen Storage Disease Type IA in humans, as well as two types of cardiac problems experienced in dogs. Dr. Conlon has also served industry sponsors by performing safety studies and regulatory consultations for clinical trial approval. Dr. Conlon was the 2014 recipient of the “See the Lights” award from the The Mathew Forbes Romer Foundation for excellence in the fight against children’s genetic diseases and is a member of the American Society of Gene and Cell Therapy.

Dr. Alonzo completed his undergraduate degree in statistics at California State Polytechnic University, San Luis Obispo and his MS and PhD in biostatistics at the University of Washington. His research interests include development of statistical methods for analysis of biomarkers, medical diagnostic tests, and screening tests, and design and analysis of clinical trials. He has published more than 220 peer-reviewed articles and four book chapters. Dr. Alonzo serves as the Group Statistician for the Children’s Oncology Group (COG), as well as lead statistician for the COG Acute Myelogeneous Leukemia Strategy Group. He was a member of the Editorial Board for Biometrical Journal, Journal of Clinical Oncology, Pediatric Blood & Cancer, and Biometrics and has served as a reviewer for 25 scientific journals. Dr. Alonzo is a Fellow of the American Statistical Association. He currently resides in Glendora, CA with his family and pet (Titan, a Maine Coon cat).

Dr. Asa co-founded the contraception program for the Association of Zoos and Aquariums (AZA) that developed into the AZA Wildlife Contraception Center and then expanded to become the AZA Reproductive Management Center (RMC). She was director of that program for almost 30 years, as well as director of the Saint Louis Zoo’s Research Department (Behavioral and Reproductive Sciences). Since retiring she has served as Chair of the RMC Advisory Board and is an affiliate scientist for the Zoo. While heading the Zoo’s research program, she also taught courses for 25 years at Washington University and Saint Louis University in Endocrinology, Behavioral Endocrinology, and Animal Behavior.

She has undergraduate degrees in Zoology and Psychology and a PhD in Endocrinology and Reproductive Physiology from the University of Wisconsin-Madison. Her post-doctoral research included studies of wolves at the University of Minnesota and of sperm ultrastructure at Rockefeller University in New York. Based on her subsequent work on feral horse fertility control for the Bureau of Land Management in Nevada, she was invited to join a National Academy of Sciences committee that evaluated BLM horse management. Because of her extensive experience in contraception, she co-edited the book, Wildlife Contraception, and is a scientific advisor for the Botstiber Institute for Wildlife Fertility Control and for the Alliance for Contraception in Cats and Dogs.

Although her research has involved numerous species, her focus has been primarily on canids (wolves and foxes) and equids (horses, zebras, and wild asses), serving as reproduction advisor for the AZA Canid and Equid Taxon Advisory Groups and the IUCN Species Survival Commission’s Canid and Equid Specialist Groups.

Dr. Baer has more than 25 years of experience in the field of laboratory animal medicine, collaborating with multiple institutions to optimize animal welfare. In her career, she has worked in many diverse capacities including as the Director of the laboratory animal program at the California Institute of Technology for 24 years, as an on-call veterinarian for NASA, and as an ad hoc site visitor for the AAALAC. She completed her MS in Veterinary Medicine and DVM at Washington State University, and is specialty board certified member of the American College of Laboratory Animal Medicine. Dr. Baer is currently the CEO of Veterinary Consulting Services, PLLC, through which she serves as the Attending Veterinarian for a number of academic and biotechnology organizations. She has extensive experience working with organizations to design, build, commission, and operate new and remodeled laboratory animal housing facilities. She has published over 20 peer-reviewed articles on various laboratory animal medicine topics and was the first author of a book, Aotus: The Owl Monkey. She has also been the recipient of three NIH infrastructure grant awards and co-authored a fourth funded award. She is currently an active member of four Institutional Animal Care and Use Committees and three Institutional Biosafety Committees.

Dr. Brake completed his BS in Biology at Muhlenberg College. After completing a PhD in Microbiology and Immunology at Hahnemann Medical University (now Drexel College of Medicine), he completed a 3-year NIH postdoctoral fellowship at SmithKline Beecham Pharmaceuticals in the field of HIV molecular genetics. He was employed as a research immunologist at SmithKline Beecham Animal Health and at Pfizer Animal Health where he held several scientific and management positions in veterinary biologics R&D.  Dr. Brake subsequently founded the veterinary biologics consulting company, BioQuest Associates, LLC. Dr. Brake currently serves as a scientific consultant to the U.S. Department of Homeland Security Science and Technology, providing technical and project management expertise for several transboundary animal and zoonotic disease countermeasure projects. Dr. Brake also provides USDA consultancy services to clients in the biotechnology and biopharmaceutical industries. He enjoys hiking, kayaking, skiing, and reading, and resides in Stowe, VT with his spouse and vocal cat Chairman Meow.

Dr. Graham Cox has been involved in veterinary vaccine research since 1983; first in the small biotech sector and later for pharmaceutical companies: CSL, Pfizer, Schering Plough/Intervet and Merck. Since 2013 he has worked as a consultant in the veterinary vaccine industry specializing in early vaccine research, clinical trials, manufacturing and regulatory affairs. Graham received a B.Sc. in protein chemistry and a Ph.D. in viral immunology from the University of Saskatchewan, Canada. Contributions to vaccine research include registering the first GnRH vaccine in the USA, attaining USDA clearance for a behavior-modifying vaccine for poultry, and demonstrating the utility of DNA vaccines in cattle. He is the author or co-author of over 20 published papers, book chapters and patents.

Dr. Morris is the American Humane Endowed Chair and a research professor in the Institute for Human-Animal Connection at the University of Denver. He holds a PhD in Molecular Biology and Biochemistry from the University of Chicago. After 20 years of preclinical and clinical cancer research, he began focusing his scientific skills on the advancement of animal health and welfare and a better understanding of the impacts of animals on humans through research; first as the Director of Research at the Animal Assistance Foundation and now as a faculty member at the Institute for Human-Animal Connection. He serves as the Principal Investigator on a wide range of studies aimed at measuring the effects of animals in a variety of therapeutic environments and the impacts of companion animals on human and community health. He has served on the Board of Directors of the Alliance for Contraception in Cats and Dogs since 2011.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada, and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a venture capital backed start-up company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer.

Linda is currently retired and an independent consultant. She is a member of the Board of Directors of Dalan Animal Health, Zoetis, and the Alliance for Contraception in Cats and Dogs, and she serves as an adjunct faculty member in the Graduate School of Endocrinology and Animal Biosciences at Rutgers University. Dr. Rhodes was honored in 2019 by receiving the Iron Paw Award, the Animal Health Corridor’s award for achievement in the animal health industry.

Amy received her Ph.D. in Experimental Pathology from USC in 1986.  She worked in biotechnology and the bone marrow transplantation/cancer diagnostics field for over 25 years. Her research focused on the detection of low numbers of tumor cells in the circulation of breast cancer patients as a means of targeting early relapse. She is the author of over 75 scientific publications and the holder of three U.S. patents.  Although most of Amy’s career was in the biotechnology industry, she spent three years developing a tissue culture system for bone marrow-derived stem cells in the laboratory of Dr. Ellen Rothenberg at Caltech.  An active USC alumna, Amy was a co-founder of the USC LGBT Alumni Association and is currently a member of the USC Board of Trustees, the Health Systems Board at Keck Medicine of USC, and the USC Verdugo Hills Hospital Foundation Board.

Don Schwartz started his career as a freelance science writer and then joined Merck & Co., Inc., one of his clients, as a manager of global marketing communications. He went on to serve as Executive Director of US Business Operations for Merial Inc., a successor company owned by Sanofi, where he had direct responsibility for business development, strategic initiatives, customer care, veterinary technical solutions, regulatory, and business analytics. He is currently the Managing Director of Elders-Rede, LLC, Animal Health Advisors. Don has extensive experience in contract negotiation, legal affairs, marketing, product management, and product development, among other business skills. During his time at Merial Inc. he was instrumental in the launch of virtually all of the company’s landmark products including IVOMEC, HEARTGARD, and FRONTLINE PLUS. Don earned an undergraduate degree (English and Biology) from Union College in Schenectady, NY, did graduate work in biology (CUNY), and then went to law school. However, he is quick to point out that he is not licensed and therefore is not a lawyer.

Dr. Richard Surosky has been engaged in gene therapy research for over twenty-five years. He began his career at Avigen, Inc., an early gene therapy company based in Alameda, CA, developing adeno-associated virus (AAV) as a vector for gene therapy. He later moved to Sangamo Therapeutics in Richmond, CA, where he served as Senior Director for the Vector Production and Development Group. He supervised the Vector Production Core team, which manufactured AAV in support of a variety of research programs. He also helped oversee GMP production of AAV at CMOs in support of Phase I/II and Phase III clinical programs. He has co-authored numerous peer-reviewed publications and presented at many scientific conferences.

Dr. Surosky received his Ph.D. from Cornell University in Molecular and Cellular Biology and did his postdoctoral research at the University of Chicago in the field of yeast molecular genetics. Dr. Surosky retired in 2021, although he continues to consult for several gene therapy companies. He lives in Oakland, CA with his wife, Mae, along with two cats. They are long-time volunteers with two local rescue groups, Hopalong and the Milo Foundation, and have fostered over 400 cats and kittens. He is also an HSUS Animal Rescue Volunteer.

Dr. Swanson was educated at the University of Texas, Austin (BS), Texas A&M University (DVM), and Louisiana State University (PhD, Animal Science). He currently leads a multi-disciplinary research team at the Cincinnati Zoo on the preservation of endangered animal species, with a primary focus on maternal and embryonic factors affecting reproductive success in felids. He participates in collaborative studies of endangered small felids in Mongolia, Thailand, South Africa, the UAE, and Brazil, and he trains foreign scientists in conservation strategies. He was Co-Chair of the Felid Taxon Advisory Group of the Association of Zoos and Aquariums for ten years and has published and spoken widely on reproductive physiology of endangered and domestic felids. Before joining the Cincinnati Zoo, Dr. Swanson completed a postdoctoral fellowship in reproductive physiology of domestic and nondomestic felids, and worked as a gamete biologist at the Conservation & Research Center, Smithsonian National Zoological Park, in Front Royal, VA. He received a five-year Special Emphasis Research Career Award from the National Center for Research Resources of the NIH. Work at the Smithsonian included examination of maternal and embryonic factors affecting reproductive success in felids. Specific studies were directed toward the application of in vitro fertilization and embryo transfer for propagation of felid models of human disease and for conservation of endangered cat species.

Marcel van Duin received his PhD from the Erasmus University in Rotterdam after which he started his scientific career in pharmaceutical research at Organon in Oss, The Netherlands, where he worked on immunological approaches to fertility control as well as the discovery of novel targets for the development of new methods for female and male fertility control. In 2001, he moved to Organon Research in Newhouse, Scotland, to become the Head of Target Discovery in cardiovascular and neuroscience therapeutic programs. In early 2003, he returned to the Netherlands to accept the position of Head of Pharmacology at Organon. In this position, he was responsible for all pharmacological research in the areas of reproductive biology, oncology, and immunology, the in vitro ADME and early toxicology group, as well as the animal research facilities. Following Organon’s acquisition by Schering-Plough in 2007, he joined the Research Leadership Team of Schering-Plough as VP and Therapeutic Area Head Women’s Health. In Oss, the Netherlands, he became the head of the Women’s Health department with research programs in male and female contraception, infertility, endometriosis, and menopausal symptoms. Following the merger with Merck in 2009, he was appointed as VP and Worldwide Discovery Head for the Women’s Health and Endocrine franchise with responsibility for the global discovery activities in this therapeutic area.

In 2012 he joined Ferring Pharmaceuticals with leadership responsibilities as VP and Therapeutic Area Head for Research in Reproductive Medicine and Maternal Health and external alliances. In May 2021 he transitioned to Organon and currently serves as Head of External Innovation and Emerging Science.

Dr. Lindsey Vansandt is a Theriogenologist at the Center for Conservation and Research of Endangered Wildlife (CREW) at the Cincinnati Zoo & Botanical Garden. Dr. Vansandt completed her undergraduate requirements at the University of Missouri-Columbia, double majoring in Animal Sciences and Biology. She spent a semester in Costa Rica studying sustainable agriculture before beginning veterinary school. Lindsey graduated from the University of Missouri’s School of Veterinary Medicine in 2008. Upon completion of veterinary school, Lindsey spent a year at the Saint Louis Zoo performing a research internship, and gained clinical experience by working at an emergency veterinary clinic. She then obtained a Ph.D. in Animal Sciences at the University of Maryland. Her dissertation research was in collaboration with the Smithsonian Conservation Biology Institute, studying spermatogonial stem cells and their applications in wildlife conservation as an alternative source for genetic preservation of rare and endangered felids. Lindsey joined CREW in the fall of 2014 as a post-doctoral scientist. Her research focuses on two main areas: (1) applying assisted reproductive technologies for the conservation and propagation of wild felids, and (2) improving the health and welfare of free-roaming and sheltered cats. Lindsey serves on the Alliance for Contraception of Cats and Dogs Ethical Review Board and is the Medical Director for the non-profit veterinary clinic Gem City Vet, which serves low-income families in the Dayton, Ohio area. During Lindsey’s tenure at CREW, she produced the first sand cat kittens and jaguar cub ever born from artificial insemination and currently serves as the Reproductive Advisor for the sand cat and Amur leopard Species Survival Plans (SSPs). Lindsey was promoted to her current position of Theriogenologist in 2018, and she continues to work on CREW’s Imperiled Cat Signature Project®.

Dr. Zahorsky-Reeves attended Cornell University both undergraduate (BS with Honors ‘90) and veterinary school (’95). She completed her PhD in Comparative and Experimental Medicine at the University of Tennessee School of Veterinary Medicine, Knoxville (’99). She worked as a post-doc in xenotransplantation genetics at the University of Southern California and Childrens Hospital Los Angeles (’99-’04). Dr. Zahorsky-Reeves now serves as the laboratory animal veterinarian in the Division of Laboratory Animal Medicine at the David Geffen School of Medicine, UCLA, and is board certified in lab animal medicine (DACLAM) (’11).

Prior to stepping into his role as Chief Executive Officer of the Michelson Found Animals Foundation, Brett served as MFA’s Chief Operating Officer for over two years.  To this work, Yates brings decades of experience with finance, nonprofit, and startup organizations. Since joining Found Animals, he has combined his passion for helping animals with expertise in strategic investments and program development. Among other projects, Yates spearheaded pioneering Found Animals initiatives such as Leap Venture Studios, the first program built to springboard innovation in the growing pet products and services industry through equity investments in for-profit startups; the Better Neighbor Project, which partners with human service organizations to develop programs that support homeless and other under-served communities and their pets; and the Pet-Inclusive Housing Initiative, which was created to field research that demonstrates the benefits of pet-friendly housing to owner/operators, residents, and communities.

Before joining the MFA executive team, Yates held progressively senior roles for companies such as First American, Fiserv, and Janus Mutual Funds. He is also an entrepreneur who has consulted for multiple startup organizations. Originally from Brea,CA, Yates holds a degree in finance from the University of Denver.